SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:1741 7015 OR L773:1741 7015
 

Sökning: L773:1741 7015 OR L773:1741 7015 > (2015-2019) > Elevated plasma cop...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004985naa a2200505 4500
001oai:lup.lub.lu.se:e076091b-0aa5-4083-acf3-cccf70efd416
003SwePub
008190521s2019 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/e076091b-0aa5-4083-acf3-cccf70efd4162 URI
0247 a https://doi.org/10.1186/s12916-019-1319-42 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Barchetta, Ilariau Sapienza University of Rome4 aut0 (Swepub:lu)med-iib
2451 0a Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity
264 c 2019-04-30
264 1b Springer Science and Business Media LLC,c 2019
520 a Introduction: Copeptin is the stable surrogate marker of vasopressin (VP), which is released in response to elevated plasma osmolality or low blood pressure. Elevated plasma copeptin levels are associated with higher risk of insulin resistance-related disorders, such as type 2 diabetes (T2DM), metabolic syndrome (MS), and cardiovascular disease, and experimental reduction of circulating VP levels is shown to significantly decrease hepatic fat content in obese rats, independently from body adiposity. However, the association between copeptin and non-alcoholic fatty liver disease and steatohepatitis (NAFLD/NASH) in humans has not been explored yet. The aim of this study was to explore the relationship between plasma copeptin and the presence/severity of NAFLD/NASH. Methods: For this study, we recruited 60 obese patients candidate to bariatric surgery for clinical purposes in which intraoperative liver biopsies were performed for diagnosing NAFLD/NASH. Circulating copeptin levels were also assessed in 60 age- and sex-comparable non-obese individuals without NAFLD at liver ultrasonography. Plasma copeptin was measured by sandwich immunoluminometric assay (Thermo Fisher Scientific). Results: Obese patients with biopsy-proven NAFLD (53%) had significantly higher copeptin levels than both obese individuals without NAFLD and non-obese subjects (ob/NAFLD+ 9.5 ± 4.9; ob/NAFLD- 6.4 ± 2.6; and non-ob/NAFLD- 7.4 ± 5.1 pmol/L; p = 0.004 and p = 0.01 respectively). Plasma copeptin concentration positively correlated with hepatic macro- and micro-vesicular steatosis (r = 0.36, p = 0.026; r = 0.31, p = 0.05), lobular inflammation (r = 0.37, p = 0.024) and significantly increased throughout degrees of NASH severity, as expressed as absence, borderline, and overt NASH at the liver biopsy (r = 0.35, p = 0.01). Greater circulating copeptin predicted the presence of NASH with OR = 1.73 (95% CI = 1.02-2.93) after multivariate adjustment for age, sex, renal function and presence of T2DM and MS components. Conclusions: Increased plasma copeptin is independently associated with the presence and severity of NAFLD and NASH, pointing to a novel mechanism behind human fatty liver disease potentially modifiable by pharmacological treatment and lifestyle intervention.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Gastroenterologi0 (SwePub)302132 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Gastroenterology and Hepatology0 (SwePub)302132 hsv//eng
653 a Antidiuretic hormone
653 a Copeptin
653 a Fatty liver
653 a Metabolic syndrome
653 a NAFLD
653 a NASH
653 a Obesity
653 a Vasopressin
7001 a Enhörning, Sofiau Lund University,Lunds universitet,Kardiovaskulär forskning - hypertoni,Forskargrupper vid Lunds universitet,Cardiovascular Research - Hypertension,Lund University Research Groups4 aut0 (Swepub:lu)med-seo
7001 a Cimini, Flavia Agatau Sapienza University of Rome4 aut
7001 a Capoccia, Danilau Sapienza University of Rome4 aut
7001 a Chiappetta, Caterinau Sapienza University of Rome4 aut
7001 a Di Cristofano, Claudiou Sapienza University of Rome4 aut
7001 a Silecchia, Gianfrancou Sapienza University of Rome4 aut
7001 a Leonetti, Fridau Sapienza University of Rome4 aut
7001 a Melander, Olleu Lund University,Lunds universitet,Kardiovaskulär forskning - hypertoni,Forskargrupper vid Lunds universitet,Cardiovascular Research - Hypertension,Lund University Research Groups4 aut0 (Swepub:lu)endo-ome
7001 a Cavallo, Maria Gisellau Sapienza University of Rome4 aut
7102 a Sapienza University of Romeb Kardiovaskulär forskning - hypertoni4 org
7730 t BMC Medicined : Springer Science and Business Media LLCg 17:1q 17:1x 1741-7015
8564 u http://dx.doi.org/10.1186/s12916-019-1319-4x freey FULLTEXT
8564 u https://bmcmedicine.biomedcentral.com/track/pdf/10.1186/s12916-019-1319-4
8564 8u https://lup.lub.lu.se/record/e076091b-0aa5-4083-acf3-cccf70efd416
8564 8u https://doi.org/10.1186/s12916-019-1319-4

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy